The Pathogenesis of IgA Nephropathy and Future Treatment Options. ft Dana Rizk, MD

renalfellow5
Published on Oct 29, 2022
Curious about the pathogenesis of IgA nephropathy and future treatment options?

Dana Rizk, MD addressed the clinical presentation of IgAN, the pathogenesis of IgAN and the autoimmune nature of the disease while speaking about the upcoming novel therapies for IgAN in this recording of the Northwestern renal grand rounds.

About Dr.Rizk:
Dr. Dana Rizk is a Professor of Medicine in the Division of Nephrology at the University of Alabama at Birmingham (UAB).

Her clinical and research interests revolve around glomerular diseases and, in particular IgA Nephropathy. She has served as the site principal investigator on many clinical trials and is part of several multi-disciplinary translational research projects focused on the role of biomarkers in IgAN. Her research efforts resulted in more than 45 peer-reviewed publications in prestigious medical journals including the New England Journal of Medicine.

Dr. Rizk has been the Director of Clinical Trials Research in the Division of Nephrology since 2015 and also serves as the Medical Director for the Clinical Trials Administrative Office at UAB.
___________________________________________________________________
About NUGoKidney Northwestern University's George M. O'Brien Kidney Research Core Center provides data, tools, and resources to promote collaborative partnerships and propel the development of transformative therapeutics for patients with kidney diseases. Connect with NUGoKidney: Sign up for NUGoKidney email newsletter: http://bit.ly/NUGoKidneyNews Visit the NUGoKidney website: http://www.nephrohub.org/ Follow NUGoKidney on Twitter: https://twitter.com/NU_Nephrology Follow NUGoKidney on Instagram: https://www.instagram.com/nu_nephrology/